Biography

Prof. Aurélien Marabelle

Prof. Aurélien Marabelle is a clinician-researcher with dual expertise in oncology and immunology. His clinical practice focuses on early-phase clinical trials developing novel immunotherapies against cancer. He serves as a senior medical oncologist and principal investigator in the Drug Development Department (DITEP) at Gustave Roussy.

Prof. Marabelle’s translational research investigates the mechanisms of action of immunotherapies, their adverse events, as well as the development of new biomarkers and novel immunotherapies. He leads the Translational Research Laboratory in Immunotherapy (LRTI), affiliated with INSERM, Université Paris-Saclay, and Gustave Roussy.

He obtained a master’s degree and a PhD in oncology and immunology from the École Normale Supérieure de Lyon, King’s College London, and the University of Lyon. He studied medicine at the University of Paris VI and received his specialist medical qualification from the University of Clermont-Ferrand. He completed a clinical fellowship at the Paediatric Haematology and Oncology Institute at the Léon Bérard Cancer Centre in Lyon, followed by a postdoctoral fellowship in Professor Ronald Levy’s laboratory at Stanford University, California.

Prof. Marabelle is an active member of the professional societies ESMO, ASCO, AACR, and SITC, where he currently serves on the Board of Directors. He is also Vice-President of the French Society for Cancer Immunotherapy (FITC).

The REMISSION project, led by Prof. Marabelle and his team, was selected for funding under the 6th call for proposals of the Hospital-University Research in Health (RHU) programme within the France 2030 plan. Its aim is to tailor immunotherapy strategies to the biology of both the tumour and its host, with the goal of advancing the development of new, effective cancer treatments.